FDA Approves Pluvicto for PSMA+ mAPMN/S Prostate Cancer
FDA Approves Pluvicto for PSMA+ mAPMN/S Prostate Cancer Oncology Nursing News
Regulatory Approvals
FDA Approval Insights: Subcutaneous Isatuximab Via an On-Body Delivery System Represents a “Game-Changer” in Multiple Myeloma: With Douglas W. Sborov, MD, MS
FDA Approval Insights: Subcutaneous Isatuximab Via an On-Body Delivery System Represents a “Game-Changer” in Multiple Myeloma: With Douglas W. Sborov,…
FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI in mAPMN/S Prostate Cancer
FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI in mAPMN/S Prostate Cancer Targeted Oncology
FDA clears autoinjector drug for home treatment of heart failure edema
FDA clears autoinjector drug for home treatment of heart failure edema Cardiovascular Business
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC Urology Times